ASX Announcement: Supply Agreement for Respiratory Products in the UK
Medical Developments International (MVP) is delighted to advise it has entered into an exclusive agreement with PSUK to supply its range of respiratory devices in the UK. The agreement includes minimum quantities for the next 3 years that will drive ongoing sales growth of MVP respiratory devices in the UK. PSUK’s parent company, Phoenix Healthcare […]
Read moreTrial conducted to evaluate newer methods of pain relief for limb injuries
SINGAPORE: A year-long trial is being conducted on two medications to ensure patients get a faster and more effective delivery of pain relief. The Singapore General Hospital (SGH) and Singapore Civil Defence Force (SCDF) will study the suitability of Penthrox and Tramadol for early pain relief. Penthrox is delivered through an inhaler while Tramadol is […]
Read moreASX Announcement: Overseas Registration and Partnership Update
Update on European Marketing Application In November 2013, Medical Developments International (MVP) submitted its regulatory dossier and Marketing Authorisation Application for review to ‘The Medicines and Healthcare Products Regulatory Agency’ (MHRA) in England. On 27 January, 2014 MVP received its first round of questions from the MHRA. We have completed our responses and we are […]
Read moreCSIRO Successful completion of first milestone
In August 2012 MVP announced it had entered into a research and development program with the CSIRO designed to introduce a new, more efficient, significantly lower manufacturing cost process for the pharmaceutical compound used in Penthrox®. We are delighted to announce the first milestone, which is to manufacture commercial grade methoxyflurane in much larger quantities […]
Read moreChairman’s and CEO’s Report
Download CEO’s & Chairman’s Report as PDF RECORD PROFIT STRONG GROWTH AND 3 CENTS FULLY FRANKED INTERIM DIVIDEND Medical Developments International Ltd. (ASX:MVP) delivered a Record Net Profit After Tax of $1,444,000 for the half year ended 31 December 2012, which represents a 25% increase on H1FY2012 ($1,156,000). The financial result represents: 23% increase in […]
Read moreASX Announcement
27 December 2012 ASX ANNOUNCEMENT Significant Developments and Opportunities in Asthma Devices Consistent with MVP’s strategy of broadening the availability and use of its core products, MVP makes the following announcement about positive developments in its asthma range of products. UPDATE ON AUSTRALIA On 31 October MVP announced the winning of a competitive tender and […]
Read moreMEDICAL DEVELOPMENTS EXPANDS INTO EUROPE
Medical Developments is pleased to announce it has established a UK subsidiary company and appointed a European Business Development Manager based in London. Initially our European Business Development Manager will capitalize on the sale of MVP’s range of Medical Device’s and in particular our leading range of Asthma Devices. This follows the recent successful signing […]
Read more